Witold Prejzner

871 total citations
33 papers, 320 citations indexed

About

Witold Prejzner is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Witold Prejzner has authored 33 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 23 papers in Genetics and 13 papers in Rheumatology. Recurrent topics in Witold Prejzner's work include Chronic Myeloid Leukemia Treatments (21 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Eosinophilic Disorders and Syndromes (11 papers). Witold Prejzner is often cited by papers focused on Chronic Myeloid Leukemia Treatments (21 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Eosinophilic Disorders and Syndromes (11 papers). Witold Prejzner collaborates with scholars based in Poland, Germany and Italy. Witold Prejzner's co-authors include Andrzej Hellmann, Andrzej Mital, Maria Bieniaszewska, Andrzej Hellmann, Agnieszka Piekarska, Alicja Sadowska‐Klasa, Renata Świątkowska−Stodulska, Jan Maciej Zaucha, Michele Baccarani and Jerzy Wojnar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Witold Prejzner

29 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Witold Prejzner Poland 10 237 218 135 45 32 33 320
Ayşe Salihoğlu Türkiye 10 146 0.6× 102 0.5× 70 0.5× 28 0.6× 89 2.8× 71 320
Giuseppina Loglisci Italy 9 191 0.8× 130 0.6× 44 0.3× 50 1.1× 59 1.8× 23 278
Dan Xu China 11 168 0.7× 73 0.3× 43 0.3× 41 0.9× 45 1.4× 43 264
Douglas Tremblay United States 10 190 0.8× 179 0.8× 65 0.5× 88 2.0× 41 1.3× 20 328
Léonardo Magro France 11 270 1.1× 116 0.5× 123 0.9× 75 1.7× 119 3.7× 43 469
Joycelyn Sim China 9 199 0.8× 117 0.5× 41 0.3× 100 2.2× 57 1.8× 19 292
Vincenzo Accurso Italy 11 107 0.5× 129 0.6× 48 0.4× 71 1.6× 75 2.3× 30 329
Sandra Lejniece Latvia 8 105 0.4× 55 0.3× 46 0.3× 17 0.4× 53 1.7× 30 192
Mariarita Sciumé Italy 9 94 0.4× 64 0.3× 37 0.3× 39 0.9× 58 1.8× 26 214
Nicoletta Villivà Italy 9 115 0.5× 132 0.6× 77 0.6× 59 1.3× 154 4.8× 15 448

Countries citing papers authored by Witold Prejzner

Since Specialization
Citations

This map shows the geographic impact of Witold Prejzner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Witold Prejzner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Witold Prejzner more than expected).

Fields of papers citing papers by Witold Prejzner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Witold Prejzner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Witold Prejzner. The network helps show where Witold Prejzner may publish in the future.

Co-authorship network of co-authors of Witold Prejzner

This figure shows the co-authorship network connecting the top 25 collaborators of Witold Prejzner. A scholar is included among the top collaborators of Witold Prejzner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Witold Prejzner. Witold Prejzner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Papayannidis, Cristina, Krzysztof Mądry, Witold Prejzner, et al.. (2024). River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia. Blood. 144(Supplement 1). 6005–6005.
2.
Zaleska, Joanna, Ewa Wasilewska, Iwona Hus, et al.. (2024). High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation. Cells. 13(8). 723–723. 1 indexed citations
3.
Zarzycka, Ewa, et al.. (2024). Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia. Leukemia & lymphoma. 65(9). 1292–1302. 1 indexed citations
4.
Prejzner, Witold, Alicja Sadowska‐Klasa, Ewa Zarzycka, et al.. (2023). The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review. Frontiers in Oncology. 13. 1228481–1228481. 4 indexed citations
5.
Canzian, Federico, Joanna Góra‐Tybor, Daniele Campa, et al.. (2022). Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia. Frontiers in Oncology. 12. 952640–952640. 3 indexed citations
6.
Prejzner, Witold, et al.. (2020). The molecular analysis of four coexistent mutations in additional sex combs like 1 (ASXL1) gene in a patient with acute myeloid leukemia. Journal of Hematopathology. 13(3). 165–168. 1 indexed citations
7.
Sadowska‐Klasa, Alicja, Agnieszka Piekarska, Witold Prejzner, Maria Bieniaszewska, & Andrzej Hellmann. (2017). Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation. Annals of Hematology. 97(3). 509–517. 36 indexed citations
8.
Mital, Andrzej, Witold Prejzner, & Andrzej Hellmann. (2016). Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases. Advances in Clinical and Experimental Medicine. 24(6). 1001–1006. 8 indexed citations
9.
Prejzner, Witold, et al.. (2015). A case of probable pulmonary osteoarthropathy from the Polish Medieval cemetery of Czarna Wielka, Disctrict of Grodzisk. International Journal of Paleopathology. 5(3). 159–165. 3 indexed citations
10.
Mital, Andrzej, Witold Prejzner, Renata Świątkowska−Stodulska, & Andrzej Hellmann. (2015). Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera – retrospective analysis of 142 consecutive cases. Thrombosis Research. 136(4). 754–757. 21 indexed citations
11.
Piekarska, Agnieszka, Lidia Gil, Witold Prejzner, et al.. (2015). Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. Annals of Hematology. 94(11). 1891–1897. 10 indexed citations
12.
Sokołowska‐Wojdyło, Małgorzata, Aleksandra G. Florek, Jan Maciej Zaucha, et al.. (2014). Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. American Journal of Therapeutics. 23(3). e749–e756. 9 indexed citations
13.
Hoffmann, Verena, Michele Baccarani, Doris Lindoerfer, et al.. (2013). The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 27(10). 2016–2022. 42 indexed citations
14.
Koren‐Michowitz, Maya, Philipp le Coutre, Justus Duyster, et al.. (2010). Activity and tolerability of nilotinib. Cancer. 116(19). 4564–4572. 19 indexed citations
15.
Chodorowski, Z, Jacek Sein Anand, Andrzej Hellmann, & Witold Prejzner. (2007). [No influence of imatinib on type 2 diabetes].. PubMed. 64(4-5). 370–1. 7 indexed citations
16.
Zaucha, Jan Maciej, et al.. (2006). Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. Clinical & Laboratory Haematology. 28(3). 208–210. 4 indexed citations
17.
Zaucha, Jan Maciej, Witold Prejzner, Sebastian Giebel, et al.. (2005). Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplantation. 36(5). 417–424. 30 indexed citations
18.
Hellmann, Andrzej, et al.. (2003). Thalidomide monotherapy or in combination with dexamethasone in patients with refractory multiple myeloma. Contemporary Oncology/Współczesna Onkologia. 5(6). 273–277.
19.
Coutre, Philipp le, Karl‐Anton Kreuzer, Il‐Kang Na, et al.. (2003). Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome. American Journal of Hematology. 73(4). 249–255. 8 indexed citations
20.
Zaucha, Jan Maciej, et al.. (1995). [Evaluation of bone marrow grafts and hemopoietic chimerism using PCR hypervariable sequencing with variable number tandem repeat sequences].. PubMed. 50(36-39). 73–4.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ayşe Salihoğlu Breakdown of academic impact, for papers by Giuseppina Loglisci Breakdown of academic impact, for papers by Dan Xu Breakdown of academic impact, for papers by Douglas Tremblay Breakdown of academic impact, for papers by Léonardo Magro Breakdown of academic impact, for papers by Joycelyn Sim Breakdown of academic impact, for papers by Vincenzo Accurso Breakdown of academic impact, for papers by Sandra Lejniece Breakdown of academic impact, for papers by Mariarita Sciumé Breakdown of academic impact, for papers by Nicoletta Villivà
Rankless by CCL
2026